Zhou met future research partner
Ian Frazer at the University of Cambridge in 1989, bonded by a mutual respect and willingness to push the limits of their research. The two considered the problem of developing a vaccine for HPV – a virus that cannot be
cultured without living tissue. Frazer convinced Zhou to join him at the
University of Queensland,
Brisbane, and in 1990 they began to use
molecular biology to synthesize particles
in vitro that could mimic the virus. In March 1991 Zhou's wife and fellow researcher,
Xiao-Yi Sun, assembled by Zhou's instructions two
proteins into a
virus-like particle (VLP), resembling the HPV shell, from which
HPV vaccine would ultimately be made. The vaccine completely protects
unexposed women against four HPV strains
responsible for 70% of
cervical cancers, which kill
about 250,000 women annually. Frazer and Zhou filed a
provisional patent in June 1991 and began work on developing the vaccine within UQ. To finance clinical trials, Australian medical company
CSL, and later
Merck, were sold partial patents. (CSL has the exclusive license to sell Gardasil in New Zealand and Australia, Merck the license elsewhere.)
GlaxoSmithKline independently used the same VLP-approach to develop Cervarix, under a later US patent, licensing Frazer's
intellectual property in 2005. == Death ==